Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
The serine/threonine kinase, GSK-3, is a promising drug discovery target for treating multiple pathological disorders. Most GSK-3 inhibitors that were developed function as ATP competitive inhibitors, with typical limitations in specificity, safety and drug-induced resistance. In contrast, substrate competitive inhibitors (SCIs), are considered highly selective, and more suitable for clinical practice. The development of SCIs has been largely neglected in the past because the ambiguous, undefined nature of the substrate-binding site makes them difficult to design. In this study, we used our previously described structural models of GSK-3 bound to SCI peptides, to design a pharmacophore model and to virtually screen the “drug-like” Zinc database (~6.3 million compounds). We identified leading hits that interact with critical binding elements in the GSK-3 substrate binding site and are chemically distinct from known GSK-3 inhibitors. Accordingly, novel GSK-3 SCI compounds were designed and synthesized with IC50 values of~1–4 μM. Biological activity of the SCI compound was confirmed in cells and in primary neurons that showed increased β-catenin levels and reduced tau phosphorylation in response to compound treatment. We have generated a new type of small molecule GSK-3 inhibitors and propose to use this strategy to further develop SCIs for other protein kinases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting less conserved substrate binding sites, as opposed to ATP binding sites, might offer advantages in terms of drug specificity, functional regulation, and safety.493,494”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [493]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, G., Bower, K. A., Ma, C., Fang, S., Thiele, C. J., & Luo, J. (2004) · The FASEB Journal · doi:10.1096/fj.04-1551fje · Cited by 310
RetractedThe protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051256o · Cited by 6,851
The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains
Hanks, S. K., Quinn, A. M., & Hunter, T. (1988) · Science · doi:10.1126/science.3291115 · Cited by 5,039
ZINC − A Free Database of Commercially Available Compounds for Virtual Screening
Irwin, J. J., & Shoichet, B. K. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049714+ · Cited by 4,058
PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints
Yap, C. W. (2011) · Journal of Computational Chemistry · doi:10.1002/jcc.21707 · Cited by 2,962
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Wolber, G., & Langer, T. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049885e · Cited by 1,954
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Hawkins, P. C. D., Skillman, A. G., Warren, G. L., Ellingson, B. A., & Stahl, M. T. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100031x · Cited by 1,607
Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M.-S., Jin, O., & Woodgett, J. R. (2000) · Nature · doi:10.1038/35017574 · Cited by 1,393
Molecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
Ikeda, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.5.1371 · Cited by 1,246
Yost, C., Torres, M., Miller, J. R., Huang, E., Kimelman, D., & Moon, R. T. (1996) · Genes & Development · doi:10.1101/gad.10.12.1443 · Cited by 1,165
Lucas, J. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.1.27 · Cited by 900
Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Roxbee Cox, L., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00025-9 · Cited by 897
Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J.-P., & Anderton, B. H. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90774-2 · Cited by 737 · cited 2×
“Phosphorylation of tau (Ser 396), a known GSK‐3 substrate in neurons [23,24] was reduced following treatment with 4‐4 as demonstrated by immunoblot analysis (Figure 7C).”
BackgroundVirtual Screening Strategies in Drug Discovery: A Critical Review
Lavecchia, A., & Giovanni, C. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990001 · Cited by 686
Crystal Structure of Glycogen Synthase Kinase 3β
Dajani, R., Fraser, E., Roe, S. M., Young, N., Good, V., Dale, T. C., & Pearl, L. H. (2001) · Cell · doi:10.1016/s0092-8674(01)00374-9 · Cited by 674
Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A.-C., Jerning, E., Markgren, P.-O., Borgegård, T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306268200 · Cited by 552
Structure of GSK3beta reveals a primed phosphorylation mechanism.
ter Haar, E., Coll, J. T., Austen, D. A., Hsiao, H.-M., Swenson, L. L., & Jain, J. (2001) · Nature Structural Biology · doi:10.1038/89624 · Cited by 458
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
Duan, J., Dixon, S. L., Lowrie, J. F., & Sherman, W. (2010) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2010.05.008 · Cited by 439
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 388
Chu, B., Soncin, F., Price, B. D., Stevenson, M. A., & Calderwood, S. K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30847 · Cited by 382
Fiol, C. J., Mahrenholz, A. M., Wang, Y., Roeske, R. W., & Roach, P. J. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47901-x · Cited by 366
Therapeutic peptides: technological advances driving peptides into development
Sato, A. K., Viswanathan, M., Kent, R. B., & Wood, C. R. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.10.002 · Cited by 362
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
Eldar-Finkelman, H., & Martinez, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00032 · Cited by 354
Self-citationDocking Screens for Novel Ligands Conferring New Biology: Miniperspective
Irwin, J. J., & Shoichet, B. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b02008 · Cited by 277
Kaidanovich-Beilin, O., Milman, A., Weizman, A., Pick, C. G., & Eldar-Finkelman, H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.008 · Cited by 276
Self-citationAvrahami, L., Farfara, D., Shaham-Kol, M., Vassar, R., Frenkel, D., & Eldar-Finkelman, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.409250 · Cited by 231
Self-citationActive site comparisons highlight structural similarities between myosin and other P-loop proteins
Smith, C. A., & Rayment, I. (1996) · Biophysical Journal · doi:10.1016/s0006-3495(96)79745-x · Cited by 221
The GSK-3 Family as Therapeutic Target for Myocardial Diseases
Lal, H., Ahmad, F., Woodgett, J., & Force, T. (2015) · Circulation Research · doi:10.1161/circresaha.116.303613 · Cited by 206
Glycogen Synthase Kinase 3β Functions To Specify Gene-Specific, NF-κB-Dependent Transcription
Steinbrecher, K. A., Wilson, W., Cogswell, P. C., & Baldwin, A. S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.19.8444-8455.2005 · Cited by 205
Docking and chemoinformatic screens for new ligands and targets
Kolb, P., Ferreira, R. S., Irwin, J. J., & Shoichet, B. K. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.08.003 · Cited by 193
Schizophrenia as a GSK-3 dysregulation disorder
Lovestone, S., Killick, R., Di Forti, M., & Murray, R. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.02.002 · Cited by 192
Taylor, S. S., Radzio‐Andzelm, E., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.13.7557015 · Cited by 188
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Rosti, G., Castagnetti, F., Gugliotta, G., & Baccarani, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.139 · Cited by 175
Colloidal Aggregation Affects the Efficacy of Anticancer Drugs in Cell Culture
Owen, S. C., Doak, A. K., Wassam, P., Shoichet, M. S., & Shoichet, B. K. (2012) · ACS Chemical Biology · doi:10.1021/cb300189b · Cited by 171
Liberman, Z., & Eldar-Finkelman, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410610200 · Cited by 170
Self-citationInsulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3
Plotkin, B., Kaidanovich‐Beilin, O., Talior‐Volodarsky, I., & Eldar-Finkelman, H. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.047381 · Cited by 159
Self-citationEldar-Finkelman, H., Argast, G. M., Foord, O., Fischer, E. H., & Krebs, E. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10228 · Cited by 141
Self-citationLi, T., Hawkes, C., Qureshi, H. Y., Kar, S., & Paudel, H. K. (2006) · Biochemistry · doi:10.1021/bi051635j · Cited by 138
Azoulay‐Alfaguter, I., Elya, R., Avrahami, L., Katz, A., & Eldar-Finkelman, H. (2014) · Oncogene · doi:10.1038/onc.2014.390 · Cited by 121
Self-citationStressed and Inflamed, Can GSK3 Be Blamed?
Jope, R. S., Cheng, Y., Lowell, J. A., Worthen, R. J., Sitbon, Y. H., & Beurel, E. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.10.009 · Cited by 121
Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery
Li, Q., & Kang, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155262 · Cited by 120
Functions of GSK-3 Signaling in Development of the Nervous System
Kim, W.-Y., & Snider, W. D. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00044 · Cited by 119
Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo
Zhu, Q., Yang, J., Han, S., Liu, J., Holzbeierlein, J., Thrasher, J. B., & Li, B. (2011) · The Prostate · doi:10.1002/pros.21300 · Cited by 98
Peptide Inhibitors Targeting Protein Kinases
Eldar-Finkelman, H., & Eisenstein, M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788682253 · Cited by 94
Self-citationRegulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3
Beurel, E., Kaidanovich-Beilin, O., Yeh, W.-I., Song, L., Palomo, V., Michalek, S. M., Woodgett, J. R., Harrington, L. E., Eldar-Finkelman, H., Martinez, A., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203057 · Cited by 86
Self-citationRevisiting protein kinase–substrate interactions: Toward therapeutic development
de Oliveira, P. S. L., Ferraz, F. A. N., Pena, D. A., Pramio, D. T., Morais, F. A., & Schechtman, D. (2016) · Science Signaling · doi:10.1126/scisignal.aad4016 · Cited by 78
A unique type of GSK-3 inhibitor brings new opportunities to the clinic
Licht-Murava, A., Paz, R., Vaks, L., Avrahami, L., Plotkin, B., Eisenstein, M., & Eldar-Finkelman, H. (2016) · Science Signaling · doi:10.1126/scisignal.aah7102 · Cited by 75
Self-citationBreen, M. E., & Soellner, M. B. (2014) · ACS Chemical Biology · doi:10.1021/cb5008376 · Cited by 66
Ilouz, R., Kowalsman, N., Eisenstein, M., & Eldar-Finkelman, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604633200 · Cited by 62
Self-citationPardo, M., Cheng, Y., Velmeshev, D., Magistri, M., Eldar-Finkelman, H., Martínez, A., Faghihi, M. A., Jope, R. S., & Beurel, E. (2017) · JCI Insight · doi:10.1172/jci.insight.91782 · Cited by 35
Self-citationLicht-Murava, A., Plotkin, B., Eisenstein, M., & Eldar-Finkelman, H. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.02.036 · Cited by 28
Self-citationUnravelling the Role of Glycogen Synthase Kinase-3 in Alzheimer’s Disease-Related Epileptic Seizures
Lin, R., Jones, N. C., & Kwan, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103676 · Cited by 27
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“493,494 For example, compound 34 demonstrated these bene fi ts. 495 As the role of GSK-3 α in promoting A β production and tau phosphorylation in AD models is recognized, selective inhibition of GSK-3 α has emerged as a promising therapeutic strategy.”
BackgroundGSK-3 and tau: a key duet in Alzheimer’s disease
Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314
“Among the most promising SCIs candidates are the novel kinase-peptide inhibitor-based SCI molecules which have been designed based on a ligand-protein binding model [187].”
BackgroundGlycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward
Arciniegas Ruiz, S. M., & Eldar-Finkelman, H. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.792364 · Cited by 127
Self-citationLi, S.-S., Sun, Q., Hua, M.-R., Suo, P., Chen, J.-R., Yu, X.-Y., & Zhao, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.719880 · Cited by 140
Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration
Rippin, I., & Eldar-Finkelman, H. (2021) · Cells · doi:10.3390/cells10020262 · Cited by 107
Self-citation
Metadata
- Authors
- Rippin, I., Khazanov, N., Ben Joseph, S., Kudinov, T., Berent, E., Arciniegas Ruiz, S. M., Marciano, D., Levy, L., Gruzman, A., Senderowitz, H., & Eldar-Finkelman, H.
- Affiliations
- Tel Aviv University (IL)
- Bar-Ilan University (IL)
- Department of Human Molecular Genetics & Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
- Israel Institute for Biological Research (IL)
- Corresponding author
- Eldar-Finkelman, Hagit
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-11-18
- Volume
- 21
- Issue
- 22
- Pages
- 8709
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7698860
- OpenAlex
- W3104987635
- Cited by
- 25
- References
- 58
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 7
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Israel Science Foundatio (1843/17)
- Israel Innovation Authority (4632)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- glycogen synthase kinase-3, substrate binding site, small-molecule kinase inhibitors, pharmacophore model, virtual screening, β-catenin, tau phosphorylation, protein kinase inhibitors, drug resistance
- MeSH terms
- Protein Domains, Animals, Binding Sites, Cells, Cultured, Humans, Kinetics, Mice, Inbred C57BL, Protein Binding, Substrate Specificity, Drug Design, Molecular Structure, Glycogen Synthase Kinase 3, Cell Line, Tumor, Protein Kinase Inhibitors, Small Molecule Libraries, Drug Discovery, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.